125 related articles for article (PubMed ID: 34920976)
1. Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model.
Perera M; Smith L; Thompson I; Breemer G; Papa N; Patel MI; Swindle P; Smith E
Eur Urol Focus; 2022 Sep; 8(5):1204-1210. PubMed ID: 34920976
[TBL] [Abstract][Full Text] [Related]
2. PSA-based machine learning model improves prostate cancer risk stratification in a screening population.
Perera M; Mirchandani R; Papa N; Breemer G; Effeindzourou A; Smith L; Swindle P; Smith E
World J Urol; 2021 Jun; 39(6):1897-1902. PubMed ID: 32747980
[TBL] [Abstract][Full Text] [Related]
3. Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data.
Hood SP; Cosma G; Foulds GA; Johnson C; Reeder S; McArdle SE; Khan MA; Pockley AG
Elife; 2020 Jul; 9():. PubMed ID: 32717179
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
[TBL] [Abstract][Full Text] [Related]
5. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
6. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
7. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study.
Chiu PK; Shen X; Wang G; Ho CL; Leung CH; Ng CF; Choi KS; Teoh JY
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):672-676. PubMed ID: 34267331
[TBL] [Abstract][Full Text] [Related]
9. Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate Cancer in A Benign Prostate Hyperplasia Cohort.
Chang CC; Chiou JK; Lin CJ; Lu K; Li JR; Chang LW; Hung SC; Cheng CL
Anticancer Res; 2024 Apr; 44(4):1683-1693. PubMed ID: 38537959
[TBL] [Abstract][Full Text] [Related]
10. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
11. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
12. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
13. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
14. Machine learning methods can more efficiently predict prostate cancer compared with prostate-specific antigen density and prostate-specific antigen velocity.
Nitta S; Tsutsumi M; Sakka S; Endo T; Hashimoto K; Hasegawa M; Hayashi T; Kawai K; Nishiyama H
Prostate Int; 2019 Sep; 7(3):114-118. PubMed ID: 31485436
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.
Cosma G; McArdle SE; Foulds GA; Hood SP; Reeder S; Johnson C; Khan MA; Pockley AG
Front Immunol; 2021; 12():786828. PubMed ID: 34975879
[TBL] [Abstract][Full Text] [Related]
16. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ
BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940
[TBL] [Abstract][Full Text] [Related]
17. Optimization of clinical risk-factor interpretation and radiological findings with machine learning for PIRADS category 3 patients.
Aussavavirojekul P; Hoonlor A; Srinualnad S
Prostate; 2022 Feb; 82(2):235-244. PubMed ID: 34783053
[TBL] [Abstract][Full Text] [Related]
18. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Vickers AJ; Till C; Tangen CM; Lilja H; Thompson IM
J Natl Cancer Inst; 2011 Mar; 103(6):462-9. PubMed ID: 21350221
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients.
Merriel SWD; Pocock L; Gilbert E; Creavin S; Walter FM; Spencer A; Hamilton W
BMC Med; 2022 Feb; 20(1):54. PubMed ID: 35125113
[TBL] [Abstract][Full Text] [Related]
20. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
